Literature DB >> 24879856

Cdk5 activity in the brain - multiple paths of regulation.

Kavita Shah1, Debomoy K Lahiri2.   

Abstract

Cyclin dependent kinase-5 (Cdk5), a family member of the cyclin-dependent kinases, plays a pivotal role in the central nervous system. During embryogenesis, Cdk5 is indispensable for brain development and, in the adult brain, it is essential for numerous neuronal processes, including higher cognitive functions such as learning and memory formation. However, Cdk5 activity becomes deregulated in several neurological disorders, such as Alzheimer's disease, Parkinson's disease and Huntington's disease, which leads to neurotoxicity. Therefore, precise control over Cdk5 activity is essential for its physiological functions. This Commentary covers the various mechanisms of Cdk5 regulation, including several recently identified protein activators and inhibitors of Cdk5 that control its activity in normal and diseased brains. We also discuss the autoregulatory activity of Cdk5 and its regulation at the transcriptional, post-transcriptional and post-translational levels. We finally highlight physiological and pathological roles of Cdk5 in the brain. Specific modulation of these protein regulators is expected to provide alternative strategies for the development of effective therapeutic interventions that are triggered by deregulation of Cdk5.
© 2014. Published by The Company of Biologists Ltd.

Entities:  

Keywords:  Alzheimer’s disease; Axonal growth; Cdk; Cdk5; Cyclins; Excitotoxicity; Learning and memory; Neurodegeneration; Neuronal migration; Pain signalling; Synaptic plasticity; Synaptogenesis; p25; p35; β-Amyloid

Mesh:

Substances:

Year:  2014        PMID: 24879856      PMCID: PMC4038939          DOI: 10.1242/jcs.147553

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  129 in total

Review 1.  A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease.

Authors:  Debomoy K Lahiri; Martin R Farlow; Kumar Sambamurti; Nigel H Greig; Ezio Giacobini; Lon S Schneider
Journal:  Curr Drug Targets       Date:  2003-02       Impact factor: 3.465

2.  Cyclin I is involved in the regulation of cell cycle progression.

Authors:  Taiki Nagano; Toshiaki Hashimoto; Akio Nakashima; Shin-ichi Hisanaga; Ushio Kikkawa; Shinji Kamada
Journal:  Cell Cycle       Date:  2013-07-11       Impact factor: 4.534

3.  Role of heat-shock factor 2 in cerebral cortex formation and as a regulator of p35 expression.

Authors:  Yunhua Chang; Päivi Ostling; Malin Akerfelt; Diane Trouillet; Murielle Rallu; Yorick Gitton; Rachid El Fatimy; Vivienne Fardeau; Stéphane Le Crom; Michel Morange; Lea Sistonen; Valérie Mezger
Journal:  Genes Dev       Date:  2006-04-01       Impact factor: 11.361

4.  Cyclin-dependent kinase 5 is required for associative learning.

Authors:  André Fischer; Farahnaz Sananbenesi; Christina Schrick; Joachim Spiess; Jelena Radulovic
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

5.  A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells.

Authors:  Ya-Li Zheng; Bing-Sheng Li; Niranjana D Amin; Wayne Albers; Harish C Pant
Journal:  Eur J Biochem       Date:  2002-09

6.  A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains.

Authors:  Huang Chun Tseng; Ying Zhou; Yong Shen; Li Huei Tsai
Journal:  FEBS Lett       Date:  2002-07-17       Impact factor: 4.124

7.  Tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules.

Authors:  Satoru Takahashi; Taro Saito; Shin-ichi Hisanaga; Harish C Pant; Ashok B Kulkarni
Journal:  J Biol Chem       Date:  2003-01-20       Impact factor: 5.157

8.  Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles.

Authors:  Anurag Tandon; Haung Yu; Linda Wang; Ekaterina Rogaeva; Christine Sato; M Azhar Chishti; Toshitaka Kawarai; Hiroshi Hasegawa; Fusheng Chen; Peter Davies; Paul E Fraser; David Westaway; Peter H St George-Hyslop
Journal:  J Neurochem       Date:  2003-08       Impact factor: 5.372

9.  The cyclin-dependent kinase 5 activator, p39, is expressed in stripes in the mouse cerebellum.

Authors:  Y-G Jeong; J L Rosales; H Marzban; R V Sillitoe; D-G Park; R Hawkes; K-Y Lee
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

10.  Fas engagement induces neurite growth through ERK activation and p35 upregulation.

Authors:  Julie Desbarats; Raymond B Birge; Manuelle Mimouni-Rongy; David E Weinstein; Jean-Sébastien Palerme; M Karen Newell
Journal:  Nat Cell Biol       Date:  2003-02       Impact factor: 28.824

View more
  75 in total

Review 1.  Calpain-1 and Calpain-2: The Yin and Yang of Synaptic Plasticity and Neurodegeneration.

Authors:  Michel Baudry; Xiaoning Bi
Journal:  Trends Neurosci       Date:  2016-02-10       Impact factor: 13.837

2.  Phosphorylation at serine 31 targets tyrosine hydroxylase to vesicles for transport along microtubules.

Authors:  Ana Jorge-Finnigan; Rune Kleppe; Kunwar Jung-Kc; Ming Ying; Michael Marie; Ivan Rios-Mondragon; Michael F Salvatore; Jaakko Saraste; Aurora Martinez
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

3.  Identification and characterization of a novel phosphoregulatory site on cyclin-dependent kinase 5.

Authors:  Brett Lee Roach; Jordan Matthew Ngo; Clariss Limso; Koyinsola Bolutife Oloja; Deepali Bhandari
Journal:  Biochem Biophys Res Commun       Date:  2018-09-11       Impact factor: 3.575

4.  Cdk5-Foxo3 axis: initially neuroprotective, eventually neurodegenerative in Alzheimer's disease models.

Authors:  Chun Shi; Keith Viccaro; Hyoung-Gon Lee; Kavita Shah
Journal:  J Cell Sci       Date:  2016-03-09       Impact factor: 5.285

5.  The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration.

Authors:  Jerel A Fields; Jeff Metcalf; Cassia Overk; Anthony Adame; Brian Spencer; Wolfgang Wrasidlo; Jazmin Florio; Edward Rockenstein; Johnny J He; Eliezer Masliah
Journal:  J Neurovirol       Date:  2017-01-19       Impact factor: 2.643

Review 6.  Tale of the Good and the Bad Cdk5: Remodeling of the Actin Cytoskeleton in the Brain.

Authors:  Kavita Shah; Sandra Rossie
Journal:  Mol Neurobiol       Date:  2017-05-13       Impact factor: 5.590

7.  The transcription factor XBP1 in memory and cognition: Implications in Alzheimer disease.

Authors:  Moustapha Cissé; Eric Duplan; Frédéric Checler
Journal:  Mol Med       Date:  2017-01-04       Impact factor: 6.354

8.  Heat shock inhibition of CDK5 increases NOXA levels through miR-23a repression.

Authors:  Trevor M Morey; Rabih Roufayel; Donald S Johnston; Andrew S Fletcher; Dick D Mosser
Journal:  J Biol Chem       Date:  2015-03-31       Impact factor: 5.157

9.  Tissue-type plasminogen activator regulates p35-mediated Cdk5 activation in the postsynaptic terminal.

Authors:  Ariel Diaz; Valerie Jeanneret; Paola Merino; Patrick McCann; Manuel Yepes
Journal:  J Cell Sci       Date:  2019-02-28       Impact factor: 5.285

10.  Characterization of the plasma proteomic profile of frailty phenotype.

Authors:  Kristina Landino; Toshiko Tanaka; Giovanna Fantoni; Julián Candia; Stefania Bandinelli; Luigi Ferrucci
Journal:  Geroscience       Date:  2020-11-17       Impact factor: 7.713

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.